Crystal structures of HIV-2 protease in complex with inhibitors containing the hydroxyethylamine dipeptide isostere  by Tong, Liang et al.
Crystal structures of HIV-2 protease in complex with
inhibitors containing the hydroxyethylamine
dipeptide isostere
Liang Tong1 *, Susan Pav 2, Suet Mui', Daniel Lamarre 3, Christiane Yoakim4,
Pierre Beaulieu4 and Paul C Anderson4
Departments of 1Medicinal Chemistry and 2Biochemistry, Boehringer Ingelheim Pharmaceuticals Inc., 900 Ridgebury Road, PO Box 368,
Ridgefield, CT 06877, USA and Departments of 3Biochemistry and 4Chemistry, Bio-Mega/Boehringer Ingelheim Research Inc.,
2100 rue Cunard, Laval, Quebec, Canada H7S 2G5
Background: The HIV protease is essential for the life
cycle of the virus and is an important target for the
development of therapeutic treatments against AIDS. The
structures of HIV protease in complex with different
inhibitors have helped in understanding the interactions
between inhibitors and the protease and in the design and
optimization of HIV protease inhibitors.
Results: We report here crystal structures at up to 1.7 A
resolution of the homodimeric HIV-2 protease in com-
plex with seven inhibitors containing the hydroxyethyl-
amine dipeptide isostere. A novel dimethylphenoxyacetyl
group that is present in some of these inhibitors is inserted
between residues 48' and 49' in the flap of the protease
and residues 29' and 30' (where a prime indicates a
residue in the second monomer), which undergo a con-
formational change to accommodate the phenyl ring of
the inhibitor.
Conclusions: This study shows that besides the residues
in the flap and residues 79-81 in the S1 substrate-binding
pocket which undergo conformational changes upon
inhibitor binding, residues 29 and 30 can also adapt their
conformation to fit certain inhibitors. Conformational
flexibility of the HIV protease plays an important role in
inhibitor binding.
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Introduction
The protease of HIV-1, the etiological agent of AIDS in
America, Europe and Asia, plays an essential role in the
life cycle of the virus [1], and has been an important tar-
get for pharmaceutical intervention in the treatment of
AIDS [2]. Many peptidomimetic inhibitors have been
designed based on the transition-state analog concept,
replacing the scissile amide bond with, for example, the
reduced amide, hydroxyethylene or hydroxyethylamine
nonhydrolyzable dipeptide isosteres. The understanding
of the interactions between inhibitors and the protease,
and the optimization of these inhibitors, have been aided
by the vast amount of knowledge available for the struc-
tures of HIV-1 protease-inhibitor complexes [3]. This
structural information has also helped in the design of a
novel series of non-peptide HIV protease inhibitors [4].
HIV-2 is found mostly in western Africa. The HIV-2
protease is a homodimer with 99 amino acid residues in
each monomer and shares 50% sequence identity with
that of HIV-1 [5]. Like the protease of HIV-1 [1], the
HIV-2 protease should be involved in the processing of
viral polyproteins and its inhibition should prevent the
maturation of infectious virions. Crystal structures of
HIV-2 protease-inhibitor complexes have recently
become available [6,7]. They show binding modes for
the inhibitor molecules that are similar to those of HIV-1
protease. The two proteases show structural differences at
residues 15-20, 34-40 and 65-73, regions away from the
substrate-binding sites and where the homology between
the two proteases is low [71. In this paper we report crys-
tal structures at up to 1.7 A resolution of HIV-2 protease
in complex with seven inhibitors containing the hydroxy-
ethylamine dipeptide isostere.
The HIV protease can catalyze the hydrolysis of the
Phe-Pro, Tyr-Pro and other peptide bonds in the gag and
gag-pol polyproteins. The inhibitors used in the current
study contain a phenylalanine analog in the P1 position
(as defined in [8]) and a proline homolog, pipecolinic
acid, in the Pl' position (Fig. 1) (PC Anderson, et al., &
C Yoakim, unpublished data). The inhibitors exhibit dif-
ferences in the group occupying the P2 and P3 positions.
The group is (quinolinecarbonyl)valyl in inhibitors 1-3
(referred to as the long inhibitors in the following discus-
sions), but this group is replaced by a novel dimethyl-
phenoxyacetyl moiety in the short inhibitors (4-8)
(Fig. 1). All of the compounds are potent inhibitors of
both HIV-1 and HIV-2 proteases (Fig. 1) (PC Anderson,
et al., & C Yoakim, unpublished data). Different modify-
ing groups can be placed on the pipecolinic ring; such
groups modulate the bioavailability of these compounds
but have little apparent effect on their potency (Fig. 1)
(PC Anderson, et al., & C Yoakim, unpublished data).
Inhibitor 7, an expected metabolic product of inhibitor
4, is also highly potent against both proteases.
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Fig. 1. HIV protease inhibitors. The long
inhibitors (1-3), contain a (quinolinecar-
bonyl)valyl group at the P2 and P3 pOSi-
tions and the short inhibitors (4-8),
contain a novel dimethylphenoxyacetyl
group.
Results and discussion
The crystal structures
In the discussion that follows, the amino acid residues in
the first monomer of the protease dimer are numbered
1-99, and those in the second monomer are numbered
1'-99'.
A total of seven crystal structures are presented here of
HIV-2 protease in complex with inhibitors containing the
hydroxyethylamine dipeptide isostere. The resolution of
the structures varies between 2.4 A and 1.7 A, and the R-
factor varies between 17.9% and 19.8% (Table 1). The
structure models have low deviations from ideality in
bond lengths and bond angles (Table 1). All the amino
acid residues assume energetically favorable main-chain
conformations (Fig. 2). The expected error in atomic
coordinates [9] for the complex with inhibitor 1, which is
refined at 1.7 A resolution, is 0.2 A (data not shown).
Having a collection of independently determined struc-
tures makes it possible to estimate the coordinate errors by
comparing the different structures. For example, the root
mean square (rms) deviation in main-chain atoms (N, Ca,
C and 0) between the complexes of inhibitors 1 and 2 is
0.22 A. Moreover, such comparisons are important in
assessing the significance of any observed differences
among the structures. A genuine structural difference
should be observed consistently in homologous structures.
The two-fold axis relating the protease monomers lies
mostly parallel to the ab plane in this tetragonal crystal
form. The angle of rotation around this axis is 179.50 for
all seven structures studied here. The translation element
along the axis is <0.1 A. The orientation of the HIV-2
protease dimer in complex with the long inhibitors dif-
fers from that in complex with the short'inhibitors by a
rotation of -0.5 around an axis mostly parallel to the c
direction of the crystal (Table 2). The crystal structures of
the different inhibitor complexes are superimposed onto
that of the complex with inhibitor 1 at 1.7 A resolution
for comparison (Table 2). The rms differences in the
positions of the C. atoms used in this superposition vary
from 0.14 A to 0.26 A (Table 2), consistent with the
Luzzati analysis [9].
The distribution of the average temperature-factor values
for the main-chain atoms of the protease is shown in
Fig. 3 for the complex with inhibitor 1. Residues around
25 and 25' have the lowest temperature-factor values,
suggesting rather rigid conformations for the catalytic
aspartate residues. The temperature-factor values for
residues 38-80 are consistently lower for the second
monomer than the first monomer. This is probably
attributable to crystal packing interactions of some of
these residues in the second molecule (39'-41', 45'-56'
and 63'-72') as well as the proximity of the quinoline
group of the inhibitor to residues 48'-49' (see below).
The binding orientation of the inhibitor
For some inhibitor complexes of HIV-1 and HIV-2 pro-
teases the inhibitors are present in two orientations in
the crystal, related by the local two-fold of the protease
dimer [3,6,7]. In the current structures only one orien-
tation of the inhibitors is observed. The 2Fo-F c elec-
tron-density map at 1.7 A resolution for the complex
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with inhibitor 1, calculated before the inhibitor was
included in the atomic model, is shown for the two
alternative orientations of the inhibitor (Fig. 4). There is
clear electron density for the quinoline group in one
orientation of the inhibitor and little density for the
alternative orientation. The pipecolinic ring would be
lying mostly outside electron density in the alternative
orientation. The electron density for the t-butyl group
has clear tri-dentate features whereas in the alternative
orientation the electron density can only fit a valine side
chain (Fig. 4).
The crystal structure of the unliganded HIV-1 protease
reveals a dimer with perfect two-fold symmetry [3];
therefore, there is only one orientation in which the
inhibitor can bind because the two monomers cannot be
distinguished in the unliganded state. The binding of an
asymmetric inhibitor will introduce asymmetry in the
HIV protease, which is likely to be localized around the
inhibitor-binding region. If the region of asymmetry is
used for packing contacts in forming the crystal, the pro-
tease-inhibitor complexes may be able to pack only in
one orientation. Consequently, the inhibitor may be
observed only in one orientation in the crystallographic
analysis. If the region of asymmetry is not used for pack-
ing contacts, the protease molecules can pack in both
orientations, and the inhibitor will then appear to be
present in both orientations.
Table 2. Superposition of HIV-2 protease structures.
Inhibitor number 1 2 3 4 5 6 7
No. of C,s in superposition 198 186 190 163 177 166 181
Rotation angle (°) 0 0.25 0.30 0.84 079 0.78 0.92
Rms deviation (A) 0 0.14 0.20 0.21 0.26 0.26 0.19
The crystal packing contacts of the protease-inhibitor
complexes under study here involve residues in the flap
(45'-56') close to the P3 position of the inhibitor. The
asymmetry of the P3 and P3 ' positions of the inhibitor,
and consequently the asymmetry of the S3 and S3' bind-
ing sites, probably lead to the preferential packing of only
one orientation of the protease dimers in this crystal
form. The 0.5 ° rotation of the long inhibitor complexes
relative to the short inhibitor complexes (see above) is
another indication of the effect of the inhibitor structures
on the packing of the crystals.
Interaction of the long inhibitors with HIV-2 protease
Three structures are reported here of HIV-2 protease
in complex with the long inhibitors. The three long
Fig. 2. Ramachandran plot for the complex with inhibitor 1 at
1.7 A resolution. Glycine residues are shown as crosses, prolines
as pentagons, and other residues as dots.
Table 1. Summary of crystallographic data.
Inhibitor number 1 2 3 4 5 6 7
Resolution (A) 1.7 2.2 2.4 2.2 2.1 2.1 2.2
Data source (C = CHESS, R = R-Axis) C+R C R C R R R
No. of crystals 2 2 1 2 1 2 1
No. of data frames 32 54 45 37 39 48 39
No. of observations 87 499 69 222 59 005 48 854 72 889 85 326 67 701
No. of unique reflections 22 846 11 300 8499 10 529 11 909 11 303 11 053
Rmerge (o/,)a 7.1 7.8 6.4 8.4 6.4 6.6 5.4
Completeness (%) 80 87 89 80 85 80 87
No. of protein and inhibitor atoms 1562 1561 1562 1554 1555 1556 1556
No. of water molecules 115 53 27 31 51 42 44
No. of reflections in refinement 22017 10158 7810 9870 11288 10610 10200
Final R-factor (%)b 19.6 18.3 17.9 18.5 19.8 19.3 18.0
Rms deviation in bond lengths (A) 0.017 0.017 0.017 0.021 0.019 0.019 0.017
Rms deviation in bond angles () 2.6 2.6 2.9 2.9 2.9 2,8 2.6
Average protein B-values (A2) 14 13 18 11 20 18 19
aRmerge = -Ilhi- <Ih >/l25lhi, where <Ih> is the average intensity of the different observations for reflection h. bR-factor = lIF - F ! F 
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Fig. 3. Plot of the average main-chain (N, C, C and 0) tempera-
ture factor values (A2) for the two HIV-2 protease monomers in
the complex with inhibitor 1. Thick line, residues 1-99; thin line,
residues 1'-99'.
Fig. 4. Electron density for inhibitor 1 at 1.7 A resolution. The
2Fo-FC electron density is shown, calculated before the inhibitor
was included in the atomic model. The atomic models for the
observed orientation of the inhibitor (thick lines) and the alterna-
tive orientation (thin lines), obtained by applying the local two-
fold axis of the protease, are also shown. The contour level is at
l. Electron density for the pyridyl group becomes visible when
the contour level is reduced to 0.5u.
inhibitors differ only in the chemical modifying group
on the pipecolinic ring. Except for the differences in
the conformations of these modifying groups (see
below), the three structures are generally in excellent
agreement with each other. The differences among the
structures are mostly within the expected errors of the
atomic coordinates. Several residues on the surface of the
protein have weak electron density, possibly attributable
to flexibility, and can assume different conformations
among the structures.
The structure of the complex with inhibitor 1 will be
used in the following discussions. As has been observed
with other peptidomimetic inhibitors [3], the long in-
hibitors are bound in the extended conformation and
occupy the S3 -S3' pockets (Fig. 5). The amide groups of
the inhibitor are hydrogen bonded to the protease dimer
either directly or through water molecules (Fig. 6a).
Besides water molecule W301 [3], another water mol-
ecule (W302) is observed in these structures and makes
hydrogen bonds to the t-butyl amido nitrogen of the
inhibitor and the main-chain amido nitrogen of residue
29. The hydroxyl of the isostere is located between the
catalytic Asp25 and Asp25' residues (Fig. 6b). The planes
of the two side-chain carboxylic acid groups are not
parallel to each other.
One face of the quinoline group of the inhibitor, in the
S3 pocket, is exposed to the solvent. The other face lies
against the phenyl group at the P1 position of the
inhibitor and the side chains of Pro81 and Ile82. The
edge of the quinoline ring is 4 A away from and per-
pendicular to the amide bond between residues 48' and
49', and is 5 A from the side chain of Phe53'. The S2 and
S2' pockets are highly hydrophobic and can accommo-
date the valine side chain or the slightly larger t-butyl
group of the inhibitor. The pyridyl ring of the modify-
ing group has weak electron density in all seven struc-
tures. It is mostly exposed to solvent and generally has
few interactions with the protease, consistent with the
observation that these varied modifying groups have
little apparent effect on the potency of the inhibitors.
The pyridyl group can assume several conformations
based on the current structure analysis. In one of the
conformations, it is parallel to and 4 A away from the
48-49 amide bond.
A comparison of the conformations of the two mono-
mers in the complex with inhibitor 1 reveals the asym-
metry in the HIV-2 protease dimer. The largest
main-chain differences occur at residues 46-55 and
79-82. The former can be ascribed to differences in crys-
tal-packing contacts (see above) and the proximity of the
quinoline ring of the inhibitor. The latter involves
residues in the S pocket and therefore could be a reflec-
tion of the asymmetry between the phenyl and the
pipecolinic side chains. Conformational differences are
apparent at several side chains on the surface of the pro-
tease, possibly representing differences in flexibility or
crystal packing. The asymmetry between the monomers
is also manifested by the difference in the distribution of
the temperature factors (Fig. 3).
Conformational flexibility of the HIV-2 protease for binding
the short inhibitors
The bound conformations of the four short inhibitors are
essentially identical except in the regions of the pyridine
or pyrimidine groups (Fig. 5). A comparison of the
amino acid residues of the protease of the four structures
showed no significant differences among them. The
structure of the complex with inhibitor 7 will be used in
the following discussions. The conformations of the
short inhibitors from the P1 to the P2' positions are simi-
lar to those of the long inhibitors (Fig. 5). The hydroxyl
of the isostere occupies the same position as that of the
long inhibitors. The second water molecule (W302) is
also observed in these structures.
The dimethylphenoxyacetyl group is bound in a groove
between the flap residues 48' and 49' and residues 27'-30'
(Fig. 7). Residues 29' and 30' move away from their
positions in the complexes with the long inhibitors to
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Fig. 5. The binding modes of the
inhibitors. (a) Overlap of the bound
conformation of the long inhibitors 1
(red), 2 (cyan) and 3 (black). (b) Overlap
of the bound conformation of the short
inhibitors 4 (black), 5 (cyan), 6 (pink)
and 7 (green). (c) Overlap of the bound
conformation of the long inhibitor 1
(red) and the short inhibitor 7 (green).
accommodate the dimethylphenoxy group. The main-
chain atoms of residue Asp29' shift by as much as 1 A
and the side-chain atoms of Asp30' shift by as much as
4 A relative to the structure of the inhibitor 1 complex.
A smaller conformational change is observed for residues
29 and 30 in the other monomer. Conformational flexi-
bility in residues 29 and 30 has not been observed pre-
viously in HIV-1 or HIV-2 proteases. A conformational
change at residue 27 was recently reported for an HIV-1
protease-inhibitor complex [10]. However, that confor-
mational change was accompanied by a 10-fold loss in
potency of the inhibitor [10], suggesting that residue 27
may not be very flexible. The conformational changes at
residues 29-30 occurred without any apparent loss in the
potency of the inhibitors (Fig. 1).
The residues in the flap region (43'-48') also undergo a
slight conformational change, possibly caused by the
removal of the quinoline group. The phenyl side chain in
the P1 position rotates slightly (roughly 20 ° in X2) in
the absence of the quinoline ring. The oxygen atom of
the phenoxy group is located close to the Cy atom of
the valine residue in the long inhibitors. One of the
methyl groups of the dimethylphenoxyacetyl moiety
probes deeper into the S2 pocket than the valine or the
t-butyl groups, whereas the other methyl group is
exposed to solvent.
Conformational flexibility of the hydroxyethylamine isostere
The inhibitors used in this study do not extend beyond
the P2' position, though the pyridyl group on the
pipecolinic ring partly occupies the S3' substrate-binding
pocket. If a P3' group is present, the opposite stereoisomer
is preferred at the hydroxyl position of the isostere for the
inhibition of HIV-1 protease [11]. Crystal structure com-
parisons between the two types of inhibitors show that
the hydroxyethylamine dipeptide isostere adopts different
conformations and that the proline or pipecolinic ring at
the P' position assumes opposite configurations at the
nitrogen atom [11]. The superposition of inhibitor 1 and
the hydroxyethylamine inhibitor JG-365 bound to HIV-1
protease [12], which contains a P3' residue, is shown in
Fig. 8. The torsion angle across the C,-C bond of the Pi
residue changes by 1200 such that the hydroxyl groups of
the isostere occupy the same position, where they can
interact with both catalytic aspartic acid residues. Further
torsion-angle changes in the next two bonds of the
isostere (1200 and 1700 respectively), and a change in the
configuration of the nitrogen atom, bring the carbonyl
oxygens of the P' residues to within 1 A of each other.
The position of W301 also shifts between the two in-
hibitor complexes. The t-butyl group of inhibitor 1 is
inserted into the S' pocket rather than following
the backbone of the P' residue of JG-365. Interestingly,
the second water molecule (W302) that bridges the
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Fig. 6. (a) Hydrogen-bonding interactions between inhibitor 1
and the protease. (b) The interactions between the hydroxyl of
the isostere and the catalytic aspartic acid residues.
interaction between inhibitor 1 and the protease occupies
the same position as the carbonyl oxygen of the P,' resi-
due of JG-365. The conformational flexibility of the
hydroxyethylamine isostere is important for the tight
binding of these two types of inhibitors to HIV protease.
Biological implications
The protease of HIV plays an essential role in the
processing of viral polyproteins, and the assembly
and maturation of infectious virions. The inhibi-
tion of HIV protease therefore represents an
important therapeutic area in the treatment of
AIDS. Many highly potent inhibitors have been
designed based on the transition-state analog con-
cept, which replaces the scissile P-P 1' amide
bond with a nonhydrolyzable isostere with tetra-
hedral geometry. The inhibitors used in the
current study contain the hydroxyethylamine
dipeptide isostere, and are active against HIV-1
and HIV-2 proteases at nanomolar concentrations.
The crystal structures of these inhibitors in com-
plex with HIV-2 protease show that they are
bound in the extended conformation, similar to
what has been observed with other peptido-
mimetic HIV protease inhibitors.
The flap residues (43-58) of the protease undergo
a large conformational change to come into con-
tact with the inhibitor (although the flaps in the
unliganded simian immunodeficiency virus (SIV)
protease can assume the closed conformation
[13]). Residues 79-81, in the S substrate-binding
pocket, have also been shown to adopt different
conformations upon binding of different inhib-
itors. The crystal structures reported in this study
suggest another region of conformational flexibil-
ity in the HIV protease. Shifts in the main-chain
and side-chain atoms of residues 29 and 30 enable
the binding of the novel, non-peptidic, dimethyl-
phenoxyacetyl group that is present in some of the
inhibitors in the current study. Understanding and
taking advantage of such conformational flexibil-
ity will be important in the design and optimiza-
tion of inhibitors of HIV protease.
Materials and methods
Crystallization
The cloning, expression, purification and crystallization of
HIV-2 protease have been described earlier [14]. Briefly, puri-
fied HIV-2 protease was concentrated to 6 mg ml- i in 10%
(v/v) aqueous Dulbecco's phosphate-buffered saline
(GIBCO/BRL, 310-4200), (pH 7.4), containing 0.02% (w/v)
NaN 3. A stock solution of the inhibitor (20 mg ml- 1) in
dimethylsulfoxide (DMSO) was further diluted with 10% (v/v)
DMSO in water to 40-50-fold molar excess of the protein.
Final dilution of the inhibitor into the enzyme solution
resulted in a 4:1 to 6:1 molar excess of the inhibitor, with a
final DMSO concentration of 4-6%. The enzyme/inhibitor
mixture was incubated for 1 h at room temperature. Crystals
were grown by the hanging-drop vapor-diffusion method. The
precipitant solution contained 0.3-0.5 M NaCl, 0.1 M sodium
acetate pH 5.4, and 0.02% NaN 3. Crystals appeared within a
week but could take several months to reach a usable size.
Except for the complex with inhibitor 8 (see below), crystals
grew as thin tetragonal prisms. The largest crystal had dimen-
sions of 0.1 mmxO.1 mmxl.5 mm, though generally crystals of
size 0.06 mmx0.06 mmxl.0 mm were used for data collection.
The crystals belong to space group P4 1212 or P43212, with
a=b=62.6 A and c=115.8 A. The crystals contain one HIV-2
protease dimer per asymmetric unit.
Crystals of the complex with inhibitor 8 grew under the same
condition as a cluster of five prisms arranged like a flower. They
belong to space group P2 13 with a=b=c=115.4 A. The crystals
contain two HIV-2 protease dimers per asymmetric unit. These
crystals diffract X-rays poorly and a reflection data set to 3.2 A
resolution was collected with an R-Axis system. The structure
was determined by molecular replacement and the inhibitor
molecules could be located in the 2F-F c electron-density maps.
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Fig. 7. Stereo plot of conformational
changes in the HIV-2 protease in com-
plexes with the short inhibitors.
Residues 27'-31' and the (quinoline-
carbonyl)valyl group of the complex
with inhibitor 1 (red) are shown super-
imposed on the corresponding residues
and the dimethylphenoxyacetyl group
of the complex with inhibitor 7 (green).
Fig. 8. Stereo plot of the superposition of
inhibitor 1 (thin lines) and JG-365 (thick
lines). The water molecules (W301 and
W302) are shown as crosses.
However, because of the relatively low resolution of the struc-
ture, this complex will not be discussed further in this paper.
Data collection and processing
X-ray diffraction data for the complexes with inhibitors 1, 3, 5,
6 and 7 were collected at 4C on an R-Axis imaging plate
detector mounted on a Rigaku RU-200 X-ray generator oper-
ated at 50 kV and 100 mA. The crystal-to-detector distance
was 100-115 mm. An oscillation range of 1.5 ° per frame was
used and the exposure time per frame was 75-110 min. The
reflection data were processed, scaled and merged with the
software provided with the R-Axis system. The data process-
ing statistics are summarized in Table 1.
X-ray diffraction data for the complexes with inhibitors 1, 2
and 4 were collected at 4C on the F-1 beamline at the
Cornell High Energy Synchrotron Source (CHESS). The
X-ray wavelength was 0.91 A. The diffraction pattern was
recorded on Fuji imaging plates, which were scanned at a raster
of 0.1 mm. The crystal-to-detector distance was 160-220 mm
and the exposure time per frame of 2 oscillation varied
between 25 s and 60 s. The data frames were integrated with
the Rossmann processing package [15]. The full observations
of the frames were scaled and merged with the program PRO-
TEIN [16]. The data-processing statistics are given in Table 1.
For the complex with inhibitor 1, the 1.7 A data set from
CHESS was scaled and merged with the 2 A data set from the
R-Axis to improve the completeness of the reflection data.
Structure determination by molecular replacement
The crystal structure of the complex with inhibitor 2 was
determined first and was used as the starting model for the
other inhibitor complexes. The model for the HIV-2 protease
dimer (Protein Data Bank [17] entry 2PHV [5]) was placed in a
P1 cell with a=b=c=100 A and ot=3='y = 90° . Reflection data
'1' ,'
40 Structure 1995, Vol 3 No 1
between 10 A and 3.5 A resolution were used in the rotation
function calculation with the program GLRF [18]. The radius
of integration was 20 A and 23% of the reflections were saved
as large terms. Two peaks were found in the rotation function
map, at Eulerian angles of (48° , 48° , 316° ) and (39° , 48° , 316° )
and with heights of 999 (arbitrary scale, 5.8cr above the aver-
age) and 976 (5.7(T) respectively. The next peak in the rotation
function had a height of 676 (3.6(r). The first peak would ori-
ent the local two-fold axis of the HIV-2 protease dimer along
the [110] direction of the unit cell, but could not lead to a
translation function solution in either space group. A clear
translation function solution, at (0.900, 0.411, 0.033), was
obtained with the second orientation in space group P4 3212.
Reflection data between 8 A and 3.5 A resolution were used in
the Patterson correlation translation-function calculation [19].
The height of the second peak in the translation function was
64% of that of the top peak. Reasonable packing of the
molecules in the unit cell provided further support for the
correctness of the solution.
Structure refinement
For the complex with inhibitor 2, rigid-body refinement with
the program X-PLOR [20] using reflections between 6 A and
4 A resolution lowered the R-factor from 45.5% to 41.4%. The
angle of rotation relating the two monomers, modeled to be
178.5° based on the HIV-1 protease structures [5], was
changed to 179.6 ° by this rigid-body refinement. A simulated-
annealing slow-cooling refinement [20] reduced the R-factor
to 21.0% for reflection data between 6.0 A and 3.0 A resolu-
tion. The atomic model was examined against the 2Fo-F c elec-
tron density map and rebuilt using the program FRODO [21].
The resolution of the data was extended to 2.5 A and then
2.2 A in subsequent rounds of simulated-annealing refinement
and model rebuilding. Residues 37-41 in both monomers were
refitted against omit maps after simulated-annealing refinement
in their absence. The R factor is 25.6% for 10158 reflections
between 6 A and 2.2 A resolution. The electron density for the
inhibitor and the conserved W301 [3] was clearly visible in the
2Fo-F c map. A cycle of simulated-annealing refinement in the
presence of the inhibitor, followed by restrained individual
temperature-factor refinement, lowered the R-factor to 21.7%.
Solvent water molecules were selected from difference elec-
tron-density maps and their positions and temperature factors
were refined. The final atomic model was obtained after one
cycle of positional refinement with TNT [22].
For the structure refinement of the other complexes, the struc-
ture of the complex with inhibitor 2 was used as the initial
atomic model. The inhibitor and the water molecules were
removed and the atomic temperature factors were set to an
overall value. The inhibitor molecule and W301 were built
into the 2Fo-F c electron-density map after one cycle of simu-
lated-annealing slow-cooling refinement. After restrained indi-
vidual temperature-factor refinement, solvent water molecules
were identified from the difference electron-density map. A
final round of refinement with TNT produced the current
atomic model. The refinement statistics are summarized in
Table 1.
The atomic coordinates have been deposited at the Brook-
haven Protein Data Bank [17] (entry names 11DA and 1DB).
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